Skip to main content
. 2011 Oct 10;102(11):1977–1990. doi: 10.1111/j.1349-7006.2011.02079.x

Figure 10.

Figure 10

 Antitumor activity of the combination of interleukin (IL)‐29 and interferon (IFN)‐αin vivo. Simultaneous administration of 50 ng IL‐29 and 20 ng IFN‐α into established OBA‐LK1 tumors inhibited growth more effectively than each reagent alone (*P <0.05; **P <0.03 vs PBS, on day 16 after therapy initiation, ***P <0.005; IL‐29 or IFN‐αvs IL‐29 plus IFN‐α). The result is representative of two independent experiments.